Efanesoctocog alfa approved to prevent and treat bleeding in children and adults with severe or moderate haemophilia A

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be used to treat and prevent bleeding in patients aged 2 years and above with s…

Follow this news feed: